七七
Lv5
1040 积分
2021-09-15 加入
-
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
9天前
已完结
-
CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer
4个月前
已完结
-
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
4个月前
已完结
-
Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma
5个月前
已关闭
-
Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study
6个月前
已关闭
-
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
6个月前
已完结
-
HLA-G-mediated immunological tolerance and autoimmunity
6个月前
已关闭
-
Lymphatic transport of proteins after s.c. injection: implications of animal model selection
9个月前
已完结
-
Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab
9个月前
已完结
-
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
10个月前
已完结